Quince Therapeutics, Inc. - Common Stock QNCX 深 滬
已收盤 08-01 16:00:00 美东时间
1.68
-0.010
-0.59%
華盛通- 最 高1.70
- 今 開1.66
- 成交量 6.11万股
- 最 低 1.63
- 昨 收 1.69
- 總市值 8759.64万
- 52周最高 2.45
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5116
- 委 比 -85.07%
- 總股本 5214.07万
- 歷史最高 121.98
- 量 比 0.41
- 振 幅 4.14%
- 歷史最低 0.5116
- 每 手 1
- 風險率 0.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial To Evaluate eDSP For Treatment Of Rare Neurodegenerative Disease Ataxia-Telangiectasia
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed
07-16 20:06
Quince Therapeutics Raises $11.5M in Private Placement
Quince Therapeutics ( ($QNCX) ) has shared an announcement. On June 12, 2025, Q...
06-14 05:46
Quince Therapeutics announces pricing of up to $22M private placement; shares up 22%
Quince Therapeutics (NASDAQ:QNCX) announces a private placement expected to generate $11.5M in upfront proceeds. The deal includes common stock (or pre-funded warrants) and accompanying common warrant...
06-13 05:31
美股大行评级 | 花旗首予霸王茶姬"买入"评级，CrowdStrike、达乐公司、Guidewire Software、Snowflake获多家机构上调评级和目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137304602125590529.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Wolfe Research：维持Cheche Group(CCG)"跑赢大市"评级，目标价从335美元升至350美元</p> <p>• HC Wainwright & Co.：上调AnaptysBio(ANAB)
06-05 09:42
Quince Therapeutics Says Pivotal Phase 3 NEAT Clinical Trial In Rare Neurodegenerative Disease A-T Reaches Important Milestone As Enrollment Now Exceeds 75%
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT
06-04 04:12
美股大行评级 | 潜在涨幅592.64%！Larimar Therapeutics获HC Wainwright升目标价至16美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111574370732224512.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Larimar Therapeutics(LRMR)"买入"评级，目标价从15美元升至16美元</p> <p>• HC Wainwright & Co.：维持Au
03-26 08:45
美股大行评级 | 潜在涨幅586.27%！HC Wainwright & Co.上调Enlivex Therapeutics目标价至7美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1111211417521721345.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Enlivex Therapeutics(ENLV)"买入"评级，目标价从6美元升至7美元</p> <p>• Maxim Group：上调Nexalin Technolo
03-25 09:37
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers HCW Biologics (NASDAQ:HCWB) shares rose 251.2% to $0.98 during Monday'...
02-04 05:05
快讯 | Quince Therapeutics任命著名的儿童神经学专家威廉·怀特豪斯博士为科学顾问委员会成员。
Quince Therapeutics Appoints Renowned Pediatric Neurologist DR. William Whiteho...
01-24 05:05
美股大行评级 | 潜在升幅197%！OBIO隔夜暴涨34.5%，获巴克莱首予超配评级，目标价16美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1081857579321679873.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调Topgolf Callaway Brands(MODG)评级至"买入"，目标价从11美元升至13美元</p> <p>• 杰富瑞：维持Xenia Hotels & Resorts(XHR)"买入"评级，
01-03 09:44
